Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Johnson multiple...

    Johnson multiple myeloma drug succeeds in first-line combination study

    Written by Ruby Khatun Khatun Published On 2017-11-23T10:00:17+05:30  |  Updated On 18 Aug 2021 2:51 PM IST

    Johnson and Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.


    The data could lead to approval of the Darzalex combination as an initial, or first-line, therapy for multiple myeloma, providing a larger sales opportunity for the medicine, one of J&J's most important growth drivers.


    Darzalex, a biotech drug known chemically as daratumumab, is already approved in combination with other medicines or alone in patients who had received one or more prior treatment regimens.


    It had third-quarter sales of $317 million, with annual sales forecast to reach about $5 billion by 2021, according to Thomson Reuters data.


    In the first-line study, 706 patients deemed not eligible for bone marrow transplant received either Darzalex with Takeda Pharmaceutical's Velcade, the chemotherapy melphalan, and the steroid prednisone or the combination without Darzalex.


    Median time until disease progression, or progression-free survival, was 18.1 months for the standard regimen but had not yet been reached for the Darzalex group, according to a summary of data to be presented next month at the American Society of Hematology (ASH) meeting in Atlanta.


    The superior PFS with Darzalex was driven by more patients achieving deep responses, including a significantly higher complete response rate, researchers concluded.


    The overall response rate was 90.9 percent for the Darzalex group, while 73.9 percent of those in the control group responded.


    The rate of complete responses, meaning no detectable cancer in the blood or bone marrow, was 42.6 percent for Darzalex versus 24.4 percent for the standard regimen.


    Overall survival data was not yet available.


    About 71 percent of Darzalex patients had what was deemed a very good partial response versus 49.7 percent for the other regimen.


    There was a higher rate of serious infections in the Darzalex group - 23.1 percent vs 14.7 percent.


    Dr. Kenneth Anderson, the ASH president, called the responses "impressive," but added they were likely to be viewed as even more significant outside of the United States.


    The trial was primarily conducted in Europe using the standard first-line regimen there. Celgene Corp's Revlimid is part of the standard regimen used in the United States.


    "It likely will be the basis for approval of daratumumab to be incorporated into the initial combination therapy of myeloma," Anderson said of the results.


    (Reporting by Bill Berkrot; Editing by Andrew Hay)

    American Society of Hematologyblood cancerbone marrow transplantchemotherapycombination studydaratumumabDarzalexDr Kenneth Andersondrugfirst lineJohnson and Johnsonmelphalanmultiple myelomasteroidsucceedsTakeda PharmaceuticalVelcade
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok